{"id":499419,"date":"2021-05-27T08:33:57","date_gmt":"2021-05-27T12:33:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\/"},"modified":"2021-05-27T08:33:57","modified_gmt":"2021-05-27T12:33:57","slug":"eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\/","title":{"rendered":"Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Leverages TURBO-ZM\u2122<\/em><br \/>\n        <em>\u00a0Synthetic Chemistry Platform for Designing Oral Macrolide-based Ribosome Modulating Agents (RMAs)<\/em><br \/>\n        \n      <\/p>\n<p align=\"center\">\n        <em>Complements ELX-02 program in Phase 2 Clinical Trials for the Treatment<\/em><br \/>\n        <em>\u00a0of Cystic Fibrosis<\/em>\n      <\/p>\n<p>WALTHAM, Mass., May  27, 2021  (GLOBE NEWSWIRE) &#8212; Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the Company has received an award of up to $2.6M from the Cystic Fibrosis Foundation.This award will help to identify optimized oral RMAs for further development in the treatment of cystic fibrosis (CF) patients with nonsense mutations.<\/p>\n<p>\u201cWe are honored to receive this funding from the Cystic Fibrosis Foundation in our ongoing commitment to identify and develop new treatments for CF. Their support of novel technologies enables critical research to advance and further evaluate the potential of the TURBO-ZM\u2122\u00a0synthetic chemistry platform to develop a new class of therapies. We have tremendous confidence in the potential of RMAs designed with TURBO-ZM\u2122\u00a0to treat rare genetic diseases,\u201d said Sumit Aggarwal, President and Chief Executive Officer. \u201cIn preclinical models, novel RMAs have demonstrated the potential for significant readthrough and functional activity.\u201d<\/p>\n<p>Mr. Aggarwal continued, \u201cIn addition, the development of a Ribosome Modulating Agent for the treatment of CF with support from the Cystic Fibrosis Foundation complements our ongoing ELX-02 program, currently in Phase 2 clinical trials. Data from these Phase 2 trials is expected in the second half of this year.\u201d<\/p>\n<p>\n        <strong>About Eloxx Pharmaceuticals<\/strong>\n      <\/p>\n<p>Eloxx Pharmaceuticals, Inc.\u00a0is engaged in the science of ribosome modulation, leveraging both its innovative TURBO-ZM\u2122\u00a0chemistry technology platform in an effort to develop novel Ribosome Modulating Agents (RMAs) and its library of Eukaryotic Ribosome Selective Glycosides (ERSGs). Eloxx\u2019s lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in clinical development focusing on cystic fibrosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx also has preclinical programs focused on select rare diseases including inherited diseases, cancer caused by nonsense mutations, kidney diseases, including autosomal dominant polycystic kidney disease, as well as rare ocular genetic disorders.<\/p>\n<p>For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=utIagT-Wq3NF1tfh8-XqsaP48pznegmeAthmIzHp1a1tdR7lIY50rmcz-oboTUuGU8VStfxh0ilFY0feNeAo0IZRpBrrMZQbxWCgOcC4u6U=\" rel=\"nofollow noopener\" target=\"_blank\">www.eloxxpharma.com<\/a>.<\/p>\n<p>\n        <strong>Forward-looking\u00a0Statements<\/strong>\n      <\/p>\n<p>\n        <em>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of present and historical facts contained in this press release, including without limitation, statements regarding the expected timing of trials and results from clinical studies of our product candidate, the expansion of our clinical trial sites and the potential of our product candidate to treat nonsense mutations are forward-looking statements. Forward-looking statements can be identified by the words \u201caim,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cexplore,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201ccontemplate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cseeks,\u201d or \u201ccontinue\u201d or the negative of these terms similar expressions, although not all forward-looking statements contain these words. <\/em>\n      <\/p>\n<p>\n        <em>Forward-looking statements are based on management&#8217;s current plans, estimates, assumptions and projections based on information currently available to us. Forward-looking statements are subject to known and unknown risks,uncertainties and assumptions, and actual results or outcomes may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to: our ability to progress any product candidates in preclinical or clinical trials; the uncertainty of clinical trial results and the fact that positive results from preclinical studies are not always indicative of positive clinical results; the scope, rate and progress of our preclinical studies and clinical trials and other research and development activities; the competition for patient enrollment from drug candidates in development; the impact of the global COVID-19 pandemic on our clinical trials, operations, vendors, suppliers, and employees; our ability to obtain the capital necessary to fund our operations; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain financial in the future through product licensing, public or private equity or debt financing or otherwise; general business conditions, regulatory environment, competition and market for our products; and business ability and judgment of personnel, and the availability of qualified personnel and other important factors discussed under the caption \u201cRisk Factors\u201d in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as any such factors may be updated from time to time in our other filings with the SEC, accessible on the SEC\u2019s website at <\/em><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kz-zcnYvOv9FRJy4aRboj9OIZv_dz55hWUY1t6hVGSzFSWgWr1tcaKLVghAiOq3mrDe1UCA6YDjCW9kyfiQamg==\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <em>www.sec.gov<\/em><br \/>\n        <\/a><br \/>\n        <em> and the \u201cFinancials &amp; Filings\u201d page of our website at <\/em><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eD4YDFBuvwXG8i-Nehh12_T24tiu2QRC245mmqmSeXM0mStHYevoB2AgPgvtvTW75FfX07KvtJ-UybtUlcL4RZd-nkOddX0JMtpZLLibN9YdbrePUI9A0_hCe4RaASKRmgOQFg3qj5oJR6PL0Xmju71apO2g5RdAo46QA5GxYnRqbHhupQTSxkePeRTpIU67U3sabDgE_Y9PPmdiTrdvWw==\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <em>https:\/\/investors.eloxxpharma.com\/financial-information\/sec-filings<\/em><br \/>\n        <\/a>\n      <\/p>\n<p>\n        <em>All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. <\/em>\n      <\/p>\n<p>\n        <strong>Contact<\/strong>\n      <\/p>\n<p>Investors<br \/>John Woolford<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=oIz7Yp4gjVOC7z05IySp9nfvs4QaHHLTWkpRtzXUImwicGjf86yia9eNd04HFOtnSXFaqq-0TFrZ15QWk9yetxJj_K69aGN1kyHMbDDv0iNhiYuQR7SvyYfAYQcNJUYB\" rel=\"nofollow noopener\" target=\"_blank\">john.woolford@westwicke.com<\/a><br \/>443.213.0506<\/p>\n<p>Media<br \/>Laureen Cassidy<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IzzUfuYpXf3yP9PSHE-Oq_m2yojdbn6gnNhLQESd5YrkPpkBLsbOAmdcr5sKyaFJMl_E4c6HLmemzWkLvHF9HsuhbPF4rf4_lPy65Tpgh1s=\" rel=\"nofollow noopener\" target=\"_blank\">laureen@outcomescg.com<\/a><\/p>\n<p>SOURCE: Eloxx Pharmaceuticals, Inc.<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDE4NiM0MjA0OTc0IzIwOTUyMDg=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/e7c6cb58-f14c-46f8-8695-2595c6937f03\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Leverages TURBO-ZM\u2122 \u00a0Synthetic Chemistry Platform for Designing Oral Macrolide-based Ribosome Modulating Agents (RMAs) Complements ELX-02 program in Phase 2 Clinical Trials for the Treatment \u00a0of Cystic Fibrosis WALTHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) &#8212; Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the Company has received an award of up to $2.6M from the Cystic Fibrosis Foundation.This award will help to identify optimized oral RMAs for further development in the treatment of cystic fibrosis (CF) patients with nonsense mutations. \u201cWe are honored to receive this funding from the Cystic Fibrosis Foundation in our ongoing commitment to identify and develop new treatments for CF. Their support of novel technologies enables &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-499419","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Leverages TURBO-ZM\u2122 \u00a0Synthetic Chemistry Platform for Designing Oral Macrolide-based Ribosome Modulating Agents (RMAs) Complements ELX-02 program in Phase 2 Clinical Trials for the Treatment \u00a0of Cystic Fibrosis WALTHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) &#8212; Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the Company has received an award of up to $2.6M from the Cystic Fibrosis Foundation.This award will help to identify optimized oral RMAs for further development in the treatment of cystic fibrosis (CF) patients with nonsense mutations. \u201cWe are honored to receive this funding from the Cystic Fibrosis Foundation in our ongoing commitment to identify and develop new treatments for CF. Their support of novel technologies enables &hellip; Continue reading &quot;Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-27T12:33:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDE4NiM0MjA0OTc0IzIwOTUyMDg=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents\",\"datePublished\":\"2021-05-27T12:33:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\\\/\"},\"wordCount\":828,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDE4NiM0MjA0OTc0IzIwOTUyMDg=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\\\/\",\"name\":\"Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDE4NiM0MjA0OTc0IzIwOTUyMDg=\",\"datePublished\":\"2021-05-27T12:33:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDE4NiM0MjA0OTc0IzIwOTUyMDg=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NDE4NiM0MjA0OTc0IzIwOTUyMDg=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\/","og_locale":"en_US","og_type":"article","og_title":"Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents - Market Newsdesk","og_description":"Leverages TURBO-ZM\u2122 \u00a0Synthetic Chemistry Platform for Designing Oral Macrolide-based Ribosome Modulating Agents (RMAs) Complements ELX-02 program in Phase 2 Clinical Trials for the Treatment \u00a0of Cystic Fibrosis WALTHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) &#8212; Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the Company has received an award of up to $2.6M from the Cystic Fibrosis Foundation.This award will help to identify optimized oral RMAs for further development in the treatment of cystic fibrosis (CF) patients with nonsense mutations. \u201cWe are honored to receive this funding from the Cystic Fibrosis Foundation in our ongoing commitment to identify and develop new treatments for CF. Their support of novel technologies enables &hellip; Continue reading \"Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-27T12:33:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDE4NiM0MjA0OTc0IzIwOTUyMDg=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents","datePublished":"2021-05-27T12:33:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\/"},"wordCount":828,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDE4NiM0MjA0OTc0IzIwOTUyMDg=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\/","name":"Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDE4NiM0MjA0OTc0IzIwOTUyMDg=","datePublished":"2021-05-27T12:33:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDE4NiM0MjA0OTc0IzIwOTUyMDg=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NDE4NiM0MjA0OTc0IzIwOTUyMDg="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/eloxx-pharmaceuticals-announces-funding-award-from-cystic-fibrosis-foundation-for-development-of-ribosome-modulating-agents\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=499419"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499419\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=499419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=499419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=499419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}